8-K: Personalis and Foresight Diagnostics Resolve Patent Litigation with Licensing Agreement

Personalis and Foresight Diagnostics have entered into a settlement and license agreement, resolving ongoing patent litigation and inter-partes review proceedings.

Summary

• Personalis and Foresight Diagnostics have reached a settlement agreement to resolve patent litigation and inter-partes review proceedings.
• Foresight has been granted a non-exclusive, worldwide license to use Personalis's patents related to whole genome sequencing and minimal residual disease panels.
• In return, Foresight will pay Personalis a low-single digit tiered royalty on net sales of products and services covered by the licensed patents.
• The license is perpetual and irrevocable, with limited exceptions on a patent-by-patent basis.
• A one-time fee in the low single-digit millions will be paid by Foresight to Personalis upon certain change of control events, along with a very low single digit increase to the highest royalty tier.
• Both companies have agreed to release each other from claims related to the litigation, IPRs, licensed patents, and related products and services.
• They have also agreed not to sue each other regarding certain products and services covered by their respective patents.

Sentiment

Score: 7

Explanation: The agreement is a positive development for both companies, resolving a legal dispute and establishing a framework for future collaboration. The royalty structure provides a potential revenue stream for Personalis, while Foresight gains access to valuable technology. However, the low royalty rate and non-exclusive nature of the license temper the overall positive sentiment.

Positives

• The settlement resolves ongoing litigation and IPRs, avoiding further legal expenses and uncertainty.
• Personalis secures a revenue stream through royalties on Foresight's sales of licensed products and services.
• Foresight gains access to Personalis's patented technology, enabling them to develop and commercialize related products.
• The perpetual and irrevocable nature of the license provides long-term stability for Foresight.
• The agreement includes a one-time payment and increased royalty rate upon certain change of control events, providing additional potential revenue for Personalis.

Negatives

• The royalty rate is a low-single digit tiered percentage, which may limit the potential revenue for Personalis.
• The license is non-exclusive, meaning Personalis can license the same technology to other companies.
• The agreement includes a covenant not to sue, which may limit Personalis's ability to pursue future patent infringement claims against Foresight related to the licensed technology.

Risks

• The royalty revenue is dependent on Foresight's success in commercializing products and services using the licensed technology.
• The agreement includes a clause allowing Personalis to terminate the license if Foresight challenges the licensed patents.
• The agreement includes a clause allowing Personalis to terminate the license if Foresight breaches the agreement by filing further IPRs.
• The agreement includes a clause allowing Personalis to terminate the license if Foresight uses Personalis's confidential information in a patent challenge.

Future Outlook

The agreement provides a framework for future collaboration and revenue generation for Personalis through royalties on Foresight's sales. The agreement also provides a framework for Foresight to develop and commercialize products using Personalis's technology.

Management Comments

• The agreement is a business resolution of the litigation and IPRs, without either party admitting any wrongdoing.
• The agreement includes a grant of certain licenses to Foresight under the Licensed Patents.
• Each party is covenanting not to sue and releasing the other party with respect to such party's CNS Patents.

Industry Context

This agreement reflects a trend in the biotechnology industry where companies resolve patent disputes through licensing agreements, allowing for continued innovation and market access. This is particularly relevant in the field of genomic sequencing and cancer diagnostics, where multiple companies are developing similar technologies.

Comparison to Industry Standards

• Licensing agreements are a common method for resolving patent disputes in the biotech industry, with royalty rates varying based on the technology and market potential.
• The low-single digit tiered royalty rate is within the range of typical biotech licensing agreements, but the specific rate is not disclosed.
• The one-time payment upon a change of control is a common provision in licensing agreements to compensate the licensor for the potential loss of future royalties.
• The perpetual and irrevocable nature of the license is a significant benefit for Foresight, providing long-term access to the technology.

Legal Proceedings

• The agreement settles previously disclosed litigation pending in U.S. federal district court.
• The agreement settles inter-partes review proceedings pending before the U.S. Patent Trial and Appeal Board.

Stakeholder Impact

• Shareholders of Personalis may view the agreement positively as it resolves litigation and provides a potential revenue stream.
• Shareholders of Foresight may view the agreement positively as it provides access to valuable technology.
• Employees of both companies may benefit from the resolution of the litigation and the potential for future growth.
• Customers of Foresight may benefit from the development of new products and services using the licensed technology.

Next Steps

• Personalis and Foresight will submit a joint stipulation to dismiss the claims of infringement in the Litigation.
• Personalis and Foresight will jointly request authorization from the PTAB to submit the necessary filings to request termination of the IPRs.
• Foresight will begin paying royalties to Personalis on net sales of products and services covered by the licensed patents.
• Foresight will pay a one-time fee to Personalis upon certain change of control events.

Key Dates

Keywords

patent litigation, licensing agreement, whole genome sequencing, minimal residual disease, royalties, settlement, inter partes review, intellectual property